Skip to main content
ozempicdiarrheaGLP-1semaglutide

Ozempic and Diarrhea: Why It Happens

Does Ozempic cause diarrhea? Why GLP-1 medications upset the gut, how long it usually lasts, when it settles, and evidence-based ways to ease it.

Medically reviewed by Linda West-Conforti, RN on July 20, 2026 CA RN #389453
Educational diagram of the digestive tract showing how GLP-1 medications affect gut motility

Yes, Ozempic can cause diarrhea. It is one of the most commonly reported side effects of semaglutide, it is usually mild and temporary, and it tends to ease as the dose is stepped up slowly and the gut adapts. If that is the answer you came for, that is the answer. The rest of this explains why it happens, what the actual numbers look like, and what helps.

Gastrointestinal effects are the reason a lot of people quit GLP-1 treatment in the first few weeks, often before the medication has had a chance to do much of anything. Understanding what is going on inside your gut makes those weeks a lot less alarming. This is general education and not medical advice, and individual results vary.

How common is diarrhea on Ozempic?

Common enough that it appears on the label. FDA prescribing information lists the most frequent adverse reactions to Ozempic, reported in at least 5% of treated patients, as nausea, vomiting, diarrhea, abdominal pain, and constipation.

The numbers depend on the dose and the population. In the pool of placebo-controlled type 2 diabetes trials summarized on the label, diarrhea was reported by 1.9% of patients on placebo, 8.5% of patients on Ozempic 0.5 mg, and 8.8% of patients on Ozempic 1 mg. Looking at gastrointestinal reactions as a whole in those same trials, the rates were 15.3% on placebo, 32.7% on 0.5 mg, and 36.4% on 1 mg.

At the higher doses used for weight management, the rates climb. A pooled analysis of the STEP 1 through STEP 3 trials, published in Diabetes, Obesity and Metabolism in 2022, examined once-weekly semaglutide 2.4 mg in 2,117 participants against 1,262 on placebo. Diarrhea was reported by 29.7% of participants on semaglutide versus 15.9% on placebo. Nausea was the most frequent effect at 43.9% versus 16.1%.

Two things are worth pulling out of that analysis. First, 99.5% of the gastrointestinal adverse events were non-serious and 98.1% were mild to moderate. Second, only 4.3% of participants on semaglutide permanently stopped treatment because of them. The effects are widespread, but for most people they are an adjustment, not a wall.

The science: why GLP-1 medications change your gut

Semaglutide is a GLP-1 receptor agonist. It imitates glucagon-like peptide-1, a hormone your intestine releases after you eat, which tells your brain you have had enough and tells your stomach to slow down.

Diagram of the semaglutide molecule, a GLP-1 receptor agonist that changes gut motility Semaglutide, a GLP-1 receptor agonist. The same signalling that reduces appetite also reaches the nerves and muscle of the digestive tract, which is why bowel habits change on treatment.

FDA prescribing information states plainly that Ozempic delays gastric emptying. That delay is not an unfortunate byproduct, it is part of how the medication works: food stays in the stomach longer, fullness lasts longer, and appetite drops.

But GLP-1 receptors are not only in the stomach and the brain. They sit throughout the gut and on the nerves that coordinate it, so the medication changes motility across the whole digestive tract, along with the secretion of fluid and bile that moves with it. That is where the seeming contradiction comes from. Slowed stomach emptying can leave the colon more time to reabsorb water, producing the constipation many people report on semaglutide. But altered intestinal rhythm and the changed handling of fluid and bile acids can just as easily push things the other way, producing looser and more urgent stools. Some people get both, alternating, especially early on.

Diet matters here too. Appetite suppression changes what people eat and when, and a gut adapting to a new signalling pattern often handles very fatty, very sugary, or very large meals poorly. You can read more about the underlying hormone pathway in our guide to how GLP-1 medications work.

When it starts and how long it lasts

The timing follows the dose. In the label’s placebo-controlled trials, the majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation. The pooled STEP analysis found the same thing: gastrointestinal events were transient and clustered during or shortly after each step up.

Semaglutide is deliberately started low and increased gradually for exactly this reason. Every increase asks the digestive system to adapt again, and that adaptation window is when symptoms show up. For most people the effects then fade as tolerance develops. In the STEP 4 trial, participants who had already tolerated a 20-week run-in found continued treatment at the maintenance dose well tolerated.

The practical takeaway is that a rough week after a dose increase is a recognized pattern, not evidence that the medication is wrong for you. What is not normal is diarrhea that keeps getting worse, does not settle, or leaves you unable to keep fluids down.

What actually helps

Most of what helps is unglamorous, and almost none of it involves changing the medication yourself.

Stay ahead on fluids. This is the one that matters most. Diarrhea pulls water and electrolytes out of you, and the label specifically advises patients to take precautions to avoid fluid depletion. Drinking steadily through the day beats catching up after the fact, and electrolytes help when losses have been significant.

Eat smaller and plainer for a few days. Large meals arriving in a stomach that is already emptying slowly tend to make everything worse. Smaller portions, spaced out, sit better. Easing off very fatty and very sugary foods for a stretch after each dose increase gives the gut less to struggle with.

Give each dose step time. Tolerance genuinely develops. The window where symptoms are worst is usually the window right after the change.

Talk to your clinician about the pace of titration. This is the real lever, and it belongs to your prescriber. Extending the time at a dose before stepping up is a standard, evidence-informed way to improve tolerability. It requires a clinician who knows your case and is reachable when something is off, which is a large part of what ongoing care is for.

What not to do: do not stop, halve, or skip a prescribed dose on your own to make the symptom go away. And be cautious with over-the-counter antidiarrheal medication without asking first, because it can mask a symptom worth evaluating.

If you want the wider picture of what to expect across all the common effects, we cover it in our guide to managing GLP-1 side effects.

When to call your clinician

Some situations need a phone call rather than patience.

Contact your care team promptly if diarrhea is severe or persistent, if you cannot keep fluids down, if you notice signs of dehydration such as dizziness, very dark urine, or urinating much less than usual, or if you have fever, blood in the stool, or severe abdominal pain. Severe abdominal pain that radiates to the back and does not stop deserves urgent attention, because pancreatitis is a labeled risk that requires prompt evaluation.

Dehydration is the reason this matters more than it might seem. FDA labeling notes postmarketing reports of acute kidney injury in patients treated with semaglutide, the majority in people who had gastrointestinal reactions leading to dehydration, and it instructs patients to promptly report persistent nausea, vomiting, or diarrhea to their healthcare provider. The route from a bad week to a real complication runs through fluid loss, which is why hydration and early reporting are the whole game.

Care that is actually reachable

A side effect like this is much easier to handle when there is a clinician on the other end who will answer, adjust the plan, and take the symptom seriously instead of leaving you to search for answers at 11pm.

That is the part REMEVi is built around: physician-led care with real follow-up, coaching through the adjustment weeks, and transparent pricing with no insurance runaround. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. Compounded semaglutide is a non-FDA-approved preparation. It is not a generic and is not the same as Ozempic®.

If you are deciding between molecules, our semaglutide vs tirzepatide breakdown lays out the differences, and you can see the full process in how REMEVi works.

Talk to a real clinician at remevihealth.com.

Your Health. Your Terms.

¿Hablas español?

Esta guía también está disponible en español, escrita por el mismo equipo clínico bilingüe.

Lee este artículo en español
Tags: ozempicdiarrheaGLP-1semaglutideozempic diarrheaside effectsweight loss

Ready to get started?

Free 1-minute quiz, then a 5-minute intake if you qualify. Clinical review in 24 hours. Medication delivered to your door.

See if you qualify

Free · about 1 minute · no card required

From $149/mo on the 52-week plan · your price never goes up See if you qualify →

Free · no card required